Se încarcă compania
Just reported
Q3 2026 results
From Maze Therapeutics's results release of 9 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
0,00 USD
Guided
—
No guide given
EPS, GAAP
Actual
-0,79 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-51,5M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Maze Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Cum face bani
- Licensing and collaboration payments
Concurează cu
Ce vinde6
MZE829
An oral drug candidate designed to block APOL1, a protein linked to kidney damage in some people with inherited APOL1 gene variants. It is being tested in people with APOL1-related kidney disease.
MZE782
An oral drug candidate that blocks a transporter involved in moving amino acids through the gut and kidneys. It is being studied for PKU and is also being developed for chronic kidney disease.
MZE001
An oral drug candidate designed to reduce glycogen buildup in muscle in people with Pompe disease. Maze licensed it to Shionogi, which is developing it.
Afișează încă 3
ATXN2 program
A gene therapy program designed to lower production of the ATXN2 gene product, which Maze studied as a possible approach to amyotrophic lateral sclerosis. Maze licensed the program to Neurocrine Biosciences.
UNC13A program
A drug research program based on the UNC13A gene and its link to amyotrophic lateral sclerosis and frontotemporal dementia. Maze licensed the program to Trace Neuroscience.
ANGPTL7 program
A research program for antibody drugs targeting ANGPTL7, a gene linked to eye pressure and glaucoma. The program is being developed by Broadwing, a company Maze formed with Alloy Therapeutics.
Cine cumpără3
- Shionogi licenses MZE001 and pays Maze development and sales milestone payments, plus royalties if the drug is sold.
- Neurocrine Biosciences licensed Maze's ATXN2 program and may pay development, regulatory, and sales milestones and royalties.
- Trace Neuroscience licensed Maze's UNC13A program and may pay development, regulatory, and sales milestones and royalties.
Pe ce se sprijină și ce l-ar putea dărâma
De ce depinde activitatea
- 1Maze relies on outside companies to run clinical trials and manufacture drug supplies for its studies.
- 2Its genetic research depends on access to genetic data paired with health information, including data accessed through agreements with the University of Helsinki.
- 3Maze has no product sales and relies on financing and licensing payments to fund research and drug development.
- 4Revenue from licensed drug programs depends on partners continuing development and reaching payment milestones or selling products.
Ce ar putea merge prost
- 1The drug candidates are still being tested; results from small or early studies may not predict whether later studies will show safety and benefit.
- 2Delays or problems at outside clinical-trial or manufacturing providers could interrupt studies or limit the supply of drugs for trials.
- 3Maze has no product sales and expects continued research and trial costs, so it may need more financing; if funding is unavailable, it may have to delay or reduce development work.
Situațiile financiare complete →
Despre Maze Therapeutics, Inc.
Maze uses human genetic and health data to find gene changes linked to disease and to identify drug targets. Its main drug candidates are designed for chronic kidney disease (CKD), including kidney disease linked to apolipoprotein L1 (APOL1), and phenylketonuria (PKU), an inherited disorder that causes harmful levels of an amino acid to build up. Maze also licenses some drug programs to other drug companies.
- Sediu
- South San Francisco, California
- Înființată în
- 2018
- Listată la
- Nasdaq
- Sfârșitul exercițiului financiar
- December 31
Construit din raportările proprii ale Maze Therapeutics, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
